Search all trials

Find therapies in clinical trials near you – page 6

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Plasma cell myeloma

Recruiting

Registered drugNo placebo

Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bortezomib

Contact Research Centre

Myelofibrosis+1

Recruiting

Registered drug

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Ruxolitinib

Contact Research Centre

Non-Hodgkin's lymphoma

Recruiting

Registered drugNo placebo

Study of MK-1045 alone or with Tocilizumab in patients with Non‑Hodgkin Lymphoma to evaluate safety and efficacy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Tocilizumab

Contact Research Centre

Duchenne muscular dystrophy

Recruiting

Investigational

Duchenne Muscular Dystrophy in Patients with Gene Mutations Amenable to Exon 44 Skipping Treated with Delpacibart Zotadirsen

Investigational

Germany

Participants:0–17 years

Contact Research Centre

Colorectal cancer metastatic

Recruiting

Registered drug

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Bevacizumab

Contact Research Centre

Chronic myeloid leukaemia

Recruiting

Registered drugNo placebo

Asciminib in Pediatric Patients With Philadelphia Positive Chronic Myeloid Leukemia in Chronic Phase

Registered drugNo placebo

Germany

Participants:0–17 years
Substances:Asciminib Hydrochloride

Contact Research Centre

Non-small cell lung cancer+1

Recruiting

Registered drugNo placebo

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Pembrolizumab

Contact Research Centre

Triple negative breast cancer+4

Recruiting

Registered drugNo placebo

Neoadjuvant Sacituzumab Govitecan and Pembrolizumab for Patients with Clinical Stage II-III Triple-Negative Early Breast Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Pembrolizumab

Contact Research Centre

Central nervous system lymphoma

Recruiting

Registered drugNo placebo

Study of Tirabrutinib, Rituximab, and Temozolomide in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Rituximab

Contact Research Centre

Obesity

Recruiting

Investigational

RO7795068 for Weight Loss in Adults With Obesity or Overweight and Type 2 Diabetes

Investigational

Germany

Participants:18–64 years · 65+ years

Contact Research Centre

Asthma

Recruiting

Investigational

GB-0895 for Severe Uncontrolled Asthma in Adults and Adolescents

Investigational

Germany

Participants:0–17 years · 18–64 years · 65+ years

Contact Research Centre

Fallopian tube cancer+2

Recruiting

Registered drugNo placebo

Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bevacizumab

Contact Research Centre

Find therapies in clinical trials near you – page 6

987 trials match your criteria

Plasma cell myeloma

Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

Myelofibrosis+1

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Non-Hodgkin's lymphoma

Study of MK-1045 alone or with Tocilizumab in patients with Non‑Hodgkin Lymphoma to evaluate safety and efficacy

Duchenne muscular dystrophy

Duchenne Muscular Dystrophy in Patients with Gene Mutations Amenable to Exon 44 Skipping Treated with Delpacibart Zotadirsen

Colorectal cancer metastatic

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Chronic myeloid leukaemia

Asciminib in Pediatric Patients With Philadelphia Positive Chronic Myeloid Leukemia in Chronic Phase

Non-small cell lung cancer+1

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Triple negative breast cancer+4

Neoadjuvant Sacituzumab Govitecan and Pembrolizumab for Patients with Clinical Stage II-III Triple-Negative Early Breast Cancer

Central nervous system lymphoma

Study of Tirabrutinib, Rituximab, and Temozolomide in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma

Obesity

RO7795068 for Weight Loss in Adults With Obesity or Overweight and Type 2 Diabetes

Asthma

GB-0895 for Severe Uncontrolled Asthma in Adults and Adolescents

Fallopian tube cancer+2

Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.